SUMMARY
Prolonged intravenous administration of high-dose barbiturates has been used for several decades in the treatment of severe head injury complicated by uncontrolled intracranial hypertension [1] [2] [3] [4] [5] [6] [7] , refractory status epilepticus 8, 9 and acute brain insults associated with cerebral ischaemia 10 . Thiopentone and its oxybarbiturate analog and metabolite, pentobarbitone, are the most commonly used barbiturates in this setting. Thiopentone demonstrates nonlinear pharmacokinetics at high doses, consistent with saturable hepatic metabolism, giving a half-life that increases as the body level increases [11] [12] [13] [14] [15] . The elimination half-life of pentobarbitone is approximately two to three times that of thiopentone 16 . Consequently, both drugs may produce a prolonged duration of unwanted pharmacological effect 17 . This may pose ethical dilemmas if decisions to modify or withdraw treatment are required when a patient's neurological status may still be influenced by plasma concentrations of one or other drug.
The relationship between plasma drug concentrations and pharmacological effect is commonly studied by pharmacokinetic-pharmacodynamic modelling techniques. To date, most pharmacokinetic-pharmacodynamic modelling of thiopen-tone has been performed in healthy volunteers or patients without severe brain injury, typically using the electroencephalogram (EEG) as a quantitative measure of the drug effect on the brain. For example, various pseudo-steady-state dose-response relationships between serum thiopentone concentrations, clinical depth of anaesthesia and EEG have been determined in healthy volunteers 17, 18 . Although both thiopentone (and pentobarbitone) are chiral drugs used as racemates for which the component enantiomers show quantitative differences in effects and in pharmacokinetics, this aspect had not been considered in most previous analyses. In a previous study of thiopentone pharmacokinetic enantioselectivity in patients requiring barbiturate neuroprotection, we used pupillary and motor responsiveness as quantitative measures of drug effect and found that the postinfusion duration of motor unresponsiveness (defined as the post-infusion time to a Glasgow Coma Score [GCS] 19 level ≥ 4) was correlated with the postinfusion duration of pupillary unresponsiveness and with elimination half-life (t½) of the thiopentone enantiomers but we were unable to distinguish a majority contribution from either enantiomer because of their pharmacokinetic similarity 20 . We also found that post-infusion times of onset of pupillary or motor responsiveness were not significantly correlated with other clinical or pharmacokinetic variables including patient age and weight, total thiopentone dose, duration or dose rate, steady state clearance (Cl ss ) or maximal serum thiopentone concentration 20 . The aim of this study was to investigate the relationship between serum thiopentone concentrations and post-infusion times to recovery of pupillary reflexes and motor responsiveness, to determine whether monitoring of serum thiopentone concentrations might have a useful role in the management of such critically ill patients. To do this, we re-examined the prospective clinical and pharmacokinetic data from 20 patients who received a high dose thiopentone infusion of greater than 24 h duration. In addition, we reviewed the records of 55 patients in whom prolonged high-dose thiopentone was given for similar indications in whom serum thiopentone concentrations had been measured but without sufficiently frequent blood sampling for a more systematic pharmacokinetic analysis.
MATERIAL AND METHODS

Demographic Data
The Human Research Ethics Committee of Royal North Shore Hospital approved the study. We prospectively studied 20 patients (13 males; seven females) with acute neurological and neurosurgical emergencies who received a high-dose intravenous thiopentone infusion of greater than 24 h duration between April 1995 and October 1997. These patients underwent systematic monitoring of serial serum thiopentone concentrations. The indication for highdose thiopentone, in nine patients, was refractory intracranial hypertension complicating severe traumatic brain injury: these patients had received standard therapy including mannitol, hyperventilation, sedation with benzodiazepines and opioids and surgical evacuation, as appropriate. Eight patients received high-dose thiopentone for angiographically verified resistant vasospasm complicating subarachnoid haemorrhage. The clinical diagnoses in the three remaining patients were sagittal sinus thrombosis, intracerebral haemorrhage complicating cerebral arterio-venous malformation and cerebral vasospasm complicating pituitary adenoma resection.
We also reviewed the medical records of all patients who had undergone some serum thiopentone concentration measurements at our institution from March 1988. We identified a further 55 patients who received prolonged high-dose thiopentone of greater than 24 h duration including 19 patients with severe head injury, 19 patients with aneurysmal subarachnoid haemorrhage and nine patients with refractory intracranial hypertension or intracerebral haemorrhage following cerebral arterio-venous malformation resection. Treatment aims and clinical monitoring for these latter groups of patients were similar to those outlined above. A breakdown showing the time of onset of pupillary and clinical recovery according to thiopentone dose rates, patient age group, gender, clinical diagnosis, GCS on admission and one-month survival for the combined cohort of patients (n=75) is given in Table 1 .
Treatment Methods and Patient Monitoring
Intravenous thiopentone was given to all 20 patients studied prospectively at a loading dose of 5 to 10 mg.kg -1 followed by a continuous infusion adjusted to maintain an EEG burst suppression pattern of 2 to 6 bursts min -1 . EEG monitoring was ceased at the completion of a thiopentone infusion. Intracranial pressure (ICP) was recorded via an intraventricular catheter connected to an external transducer system. Intravenous noradrenaline (2 to 8 µg.min -1 ) was routinely introduced following commencement of thiopentone and its dose rate adjusted to support mean arterial pressure (MAP) and cerebral perfusion pressure (CPP) (defined as the difference between MAP and ICP). The thiopentone infusion was ceased when a patient's clinical status was determined to be stable with indications of controlled intracranial pressure or relief of vasospasm.
All patients underwent hourly clinical neurological assessments, including reactivity of pupillary responses to light and motor responses to verbal command and painful stimuli, during and following the course of an infusion until discharge from the intensive therapy unit. Recovery of clinical responsiveness was deemed to have occurred if an individual patient demonstrated a motor response to pain.
Serum Thiopentone Concentration Measurements and Pharmacokinetic Analysis
The 20 patients studied prospectively underwent serial serum thiopentone concentration measurements using high performance liquid chromatography (HPLC) during and following a thiopentone infusion as previously described 21 . The mean total number of blood samples collected from these patients was 14 (SD 4), including a mean of 10 (SD 4) post-infusion samples. Serum thiopentone concentration values that were requested by the treating intensive care team were routinely made available within 24 h of that sample collection. An independent observer confirmed pupil reactivity and GCS at the times of each individual blood sample collection. Serum thiopentone concentrations were compared to the times of recovery of pupillary and motor responses following completion of an infusion. As noted above, thiopentone is a racemate with its R-(+)-and S-(-)-enantiomers having measurable differences in potency 22, 23 and pharmacokinetics 14, 20, 24, 25 . Although the serum concentrations of thiopentone enantiomers were measured in these 20 patients, they were reported to the treatment team and are reported in this paper as the sum of R-(+) and S-(-) enantiomers to be consistent with existing guidelines and literature, as well as the data of patients included from retrospective analysis before the enantiospecific assay became available.
Pharmacokinetic analysis included determination of thiopentone clearance (Cl ss , defined as the ratio of the average thiopentone dose rate for the last 12 h of thiopentone therapy to average serum concentration measured during this period) and maximal serum thiopentone concentration (C max ) observed during the course of an infusion.
Statistical Analysis
Serum thiopentone concentration values from 16 survivors studied prospectively were pooled for logistic regression analysis 26, 27 of the relationship between serum thiopentone concentrations and the absence of pupillary and motor responses. A total of 182 serum thiopentone concentration values were used in the logistic regression equations. Concentration values [C] for which pupillary reactivity or motor responses were present were given a response score of 0 and concentration values for which there was loss of pupillary or motor responses were given a response score of 1. The slope of the logistic function (γ) and median effective concentrations (EC 50 ) were derived from the Hill equation optimized to a log likelihood criterion (Equation (i) 20 and EC 5 were also calculated to indicate the effective concentrations associated with 95, 80, 20 and 5% probabilities of recovery of response.
where EC 50 is the median effective serum thiopentone concentration or concentration at which the probability of a response score of 0 is 50%, Regression analysis was performed to examine relationships between the outcome variables, i.e., times of recovery of pupillary and motor responsiveness, and between the outcome variables and clinical and pharmacokinetic variables including total thiopentone dosage, duration and dose rate, patient age, gender, total body weight, Cl ss and C max . Both linear and non-linear empirical bivariate and multivariate (best subset) equations were used [respectively, equations (ii), (iii) and (iv), initially chosen on the basis of inspection of the data] and the best fitting equations were selected from a range of possibilities on the basis of the adjusted R 2 values 27 . P values <0.05 were taken as statistically significant. 
RESULTS
In the prospective cohort of 20 patients dosed to an EEG burst suppression end point, 16 patients survived. Overall, the mean total thiopentone dose was 41.2 g (SD 19.1; 95% CI 32.3 to 50.2), mean duration of infusion was 95 h (SD 65; 95% CI 65 to 126), and mean total dose rate was 0.50 g.h -1 (SD 0.22; 95% CI 0.39 to 0.60). The mean serum thiopentone C max was 73 mg.l -1 (SD 33, 95% CI 57 to 89) and mean Cl ss was 0.102 l.min -1 (n=20, SD 0.05 95% CI 0.07 to 0.12). The mean times of recovery of pupillary and motor responsiveness were 22 h (n=16, SD 18, 95% CI 13 to 32) and 91 h (n=16, SD 46, 95% CI 67 to 116), respectively. EEG burst suppression pattern was achieved following commencement of thiopentone therapy in 19 patients; in one patient, an iso-electric EEG pattern was evident prior to and during the course of an infusion (thiopentone C max 121 mg.l -1 ). In one patient (thiopentone C max 155 mg.l -1 ), transition to iso-electric EEG occurred during infusion at a thiopentone serum concentration of 90 mg.l -1 and in another three patients at serum concentrations ranging from 60 to 80 mg.l -1 . Post-infusion pupillary reactions were absent and GCS remained at 3 following cessation of thiopentone in the four patients who died, hence they were not included in the pooled logistic regression analysis of serum thiopentone concentration pupillary and motor response data. Overall, 21 of a total 75 patients who received prolonged high-dose thiopentone over a 10-year period at our institution died, including 13 patients with fixed, unreactive pupils and a GCS of 3 at the time of death.
For the prospective cohort of 20 patients, Figure 1 shows the relationship between their serum thiopentone concentrations and recovery of pupillary and motor responses along with the best fitting pooled logistic regression analysis models. From these models, the EC 50 for the recovery of pupil reactivity was 50 mg.l -1 (γ=5. ). For the combined patient cohorts (n=75) nonlinear regression analysis found the times of recovery of motor and pupillary responsiveness to be significantly associated (Figure 2 ). Linear regression analysis found the times to recovery of both pupillary and motor responsiveness were weakly associated with total thiopentone dose rate. The post-infusion time of recovery of motor responsiveness was associated with thiopentone C max and inversely with thiopentone Cl ss . The post-infusion time of recovery of motor responsiveness was associated with thiopentone C max but the relationship between time of recovery of pupillary responsiveness and thiopentone C max did not quite achieve statistical significance (Figure 3) . Details of the best fitting regression equations, adjusted R 2 and P values are given in Table 2 . Best subset regression analysis of relationships between patient data and thiopentone pharmacokinetic data indicated that patient factors alone were poorly predictive (equation (IV), maximum adjusted R 2 =0.10) and that the addition of dosing information was still only weakly predictive (maximum adjusted R 2 =0.24) of the post-infusion time of recovery of motor responsiveness. The strongest prediction (maximum adjusted R 2 =0.63) was found in an equation that included thiopentone Cl ss , C max , total thiopentone dose rate and patient weight.
DISCUSSION
The role of barbiturates in acute cerebral insults, in particular refractory intracranial hypertension complicating severe head injury, remains contentious due to a number of studies quoting poor outcomes and serious complications [3] [4] [5] 7 . Barbiturates are no longer as widely used for sedation of critically ill patients as before, having largely been supplanted by drugs such as propofol and midazolam [28] [29] [30] [31] that have better pharmacokinetic profiles, in particular a higher total body clearance. Thiopentone and other barbiturates, however, possess theoretical pharmacological benefits as neuroprotective agents and hence continue to be used in critically ill patients with acute neurological and neurosurgical emergencies and with status epilepticus 11, 12, [32] [33] [34] [35] . We have recently reported encouraging results in patients with refractory vasospasm following subarachnoid haemorrhage 36 . Nevertheless, the most effective dose and duration of thiopentone for treatment of acute cerebral insults remains unknown and dosage regimens in the majority of clinical studies have been guided by ICP response and the ability to maintain stable haemodynamics. A pseudo-steady-state dose-response relationship between serum thiopentone concentrations, a surrogate measure of "clinical depth of anaesthesia" and EEG has been previously demonstrated in healthy volunteers 17 . Serum thiopentone concentrations of >50 mg.l -1 , for instance, result in marked EEG slowing and/or isoelectric EEG pattern and serum thiopentone concentrations. Concentrations >15 mg.l -1 have a 50% probability of inhibiting motor responses to verbal commands 17, 18 . A concentration-EEG burst-suppression relationship has also been demonstrated for a number of other barbiturates in patients with acute cranio-cerebral injuries 13, 37, 38 . In contrast, concentration and clinical effect relationships in patients with acute cerebral insults are less well defined, although previous studies have suggested that there is an association between plasma thiopentone concentrations and loss of pupillary reflexes to light or movement responses to noxious stimuli 13, 15 . Our study indicated that serum thiopentone concentrations >50 mg.l -1 are associated with absent pupillary responsiveness and those >12 mg.l -1 are associated with absent motor responsiveness. It is noteworthy that the thiopentone C max , based empirically on a thiopentone dose rate sufficient to achieve EEG burst suppression in the 20 patients studied prospectively, was 73 mg. tone concentrations may help guide decisions about the extent to which drug effect is responsible for the absence of pupillary and motor responses in patients with acute brain injury.
The desire to produce burst-suppression as an EEG end-point was probably a major contributing factor to the wide inter-individual variability seen in thiopentone dose rate requirements and thiopentone C max . The inter-patient range of serum thiopentone concentrations associated with EEG burst suppression was 42 to 90 mg.l -1 . Hence, the use of this (readily determined) EEG end-point could have predisposed most of the patients to a phenomenon termed "runaway accumulation", in which serum thiopentone concentrations increase despite a constant infusion rate due to the administration of a thiopentone dose rate greater than its maximal rate of metabolism 20 . The ability to predict post-infusion recovery times for pupillary or motor responsiveness was maximized when models were constructed from combined patient, dosing and pharmacokinetic information. It is intuitive that the intensity of response was in some way related to thiopentone C max and that the duration of response was inversely associated with thiopentone Cl ss . Nevertheless we found difficulty in reliably predicting the post-infusion duration of clinical effect. This most probably reflects the heterogeneity of pathology in the patient population and their responses to the treatment regimens, as well as the inter-individual variability in the various parameters of thiopentone pharmacokinetics 20 . Whilst maintaining a serum thiopentone concentration of <50 mg.l -1 during the course of an infusion will not necessarily protect an individual patient from a prolonged post-infusion pharmacological effect, it may help. Therapeutic drug monitoring should probably be considered a routine part of patient management, especially if surrogate measures such as EEG monitoring demonstrate an iso-electric pattern or are unavailable. Monitoring thiopentone concentration may allow better prognostication. If excess dosing can be avoided it is also possible that the cost of treatment may be reduced and patients will be exposed to less risk of ICU-related complications.
From a hypothetical perspective, the clinical effect of thiopentone could be influenced by its metabolite pentobarbitone, which has a longer elimination t 1 ¼2. It has been previously demonstrated that blood pentobarbitone concentrations of 25 to 35 mg.l -1 are effective in reducing intracranial pressure in patients with severe head injury 1 . Plasma pentobarbitone concentrations ranging from 25 to 75 mg.l -1 have also been shown to produce an EEG burst suppression pattern in severe head injury patients 37, 38 . In contrast, in vitro and in vivo studies of thiopentone suggest that the maximal rate of reduction of cerebral oxygen metabolism and neuroprotection mediated by other mechanisms, including inhibition of presynaptic glutamate release, post-synaptic glutamate activity at NMDA receptors and lipid peroxidation require serum thiopentone concentrations >50 mg.l -1 [39] [40] [41] [42] [43] . Determination of the clinical significance of equivalent serum thiopentone and pentobarbitone concentrations (expressed as mg.l -1 ), however, is complicated by the fact that the two drugs have different unbound serum fractions (30 to 40% for pentobarbitone versus 10 to 20% for thiopentone) and are potentially different mixtures of enantiomers with in vitro and in vivo differences in potency (S-(-)-thiopentone >R-(+)-thiopentone and S-(-)-pentobarbitone >R-(+)-pentobarbitone) 22 . Because of the relatively low concentrations of metabolite pentobarbitone 20, 25 , and because of the lower potency of pentobarbitone at the receptor level 22 , we are unconvinced that it makes a significant contribution to the effect of thiopentone in this context.
In conclusion, the findings in our study indicate that high-dose intravenous thiopentone aimed at achieving EEG burst suppression is very likely to result in a prolonged duration of clinical effect including loss of pupillary and motor responsiveness. In the majority of patients with acute and severe brain insults, residual drug effect should be considered a significant contributing factor to the absence of pupillary or motor responsiveness if serum thiopentone concentrations exceed 50 mg.l -1 and 12 mg.l -1 respectively. However, it needs to be re-emphasized that these are median values and the inter-individual variability is sufficiently large that "lower" serum concentrations do not necessarily indicate a poor prognosis and hence should be interpreted with caution. As the factors associated with a prolonged post-infusion duration of barbiturate effect include a higher drug C max and a lower Cl ss we believe that monitoring of serial serum thiopentone concentration is useful in this therapy. 
